Toward a structure-based model of salvinorin A recognition of the κ-opioid receptor

Brian E. Kane, Christopher R. McCurdy, David M. Ferguson

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The structural basis to salvinorin A recognition of the κ-opioid receptor is evaluated using a combination of site-directed mutagenesis and molecular-modeling techniques. The results show that salvinorin A recognizes a collection of residues in transmembrane II and VII, including Q115, Y119, Y313, I316, and Y320. The mutation of one hydrophobic residue in particular, I316, was found to completely abolish salvinorin A binding. As expected, none of the residues in transmembrane III or VI commonly associated with opiate recognition (such as D138 or E297) appear to be required for ligand binding. On the basis of the results presented here and elsewhere, a binding site model is proposed that aligns salvinorin A vertically within a pocket spanning transmembrane II and VII, with the 2′ substituent directed toward the extracellular domains. The model explains the role that hydrophobic contacts play in binding this lipophilic ligand and gives insight into the structural basis to the μ-opioid receptor selectivity of 2′-benzoyl salvinorin (herkinorin).

Original languageEnglish (US)
Pages (from-to)1824-1830
Number of pages7
JournalJournal of Medicinal Chemistry
Volume51
Issue number6
DOIs
StatePublished - Mar 27 2008

Fingerprint

salvinorin A
Opioid Receptors
Opiate Alkaloids
Ligands
Mutagenesis
Molecular modeling
Site-Directed Mutagenesis
Binding Sites
Mutation

Cite this

Toward a structure-based model of salvinorin A recognition of the κ-opioid receptor. / Kane, Brian E.; McCurdy, Christopher R.; Ferguson, David M.

In: Journal of Medicinal Chemistry, Vol. 51, No. 6, 27.03.2008, p. 1824-1830.

Research output: Contribution to journalArticle

@article{fffebd0402b34945875e9e2f7989dcfb,
title = "Toward a structure-based model of salvinorin A recognition of the κ-opioid receptor",
abstract = "The structural basis to salvinorin A recognition of the κ-opioid receptor is evaluated using a combination of site-directed mutagenesis and molecular-modeling techniques. The results show that salvinorin A recognizes a collection of residues in transmembrane II and VII, including Q115, Y119, Y313, I316, and Y320. The mutation of one hydrophobic residue in particular, I316, was found to completely abolish salvinorin A binding. As expected, none of the residues in transmembrane III or VI commonly associated with opiate recognition (such as D138 or E297) appear to be required for ligand binding. On the basis of the results presented here and elsewhere, a binding site model is proposed that aligns salvinorin A vertically within a pocket spanning transmembrane II and VII, with the 2′ substituent directed toward the extracellular domains. The model explains the role that hydrophobic contacts play in binding this lipophilic ligand and gives insight into the structural basis to the μ-opioid receptor selectivity of 2′-benzoyl salvinorin (herkinorin).",
author = "Kane, {Brian E.} and McCurdy, {Christopher R.} and Ferguson, {David M.}",
year = "2008",
month = "3",
day = "27",
doi = "10.1021/jm701040v",
language = "English (US)",
volume = "51",
pages = "1824--1830",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - Toward a structure-based model of salvinorin A recognition of the κ-opioid receptor

AU - Kane, Brian E.

AU - McCurdy, Christopher R.

AU - Ferguson, David M.

PY - 2008/3/27

Y1 - 2008/3/27

N2 - The structural basis to salvinorin A recognition of the κ-opioid receptor is evaluated using a combination of site-directed mutagenesis and molecular-modeling techniques. The results show that salvinorin A recognizes a collection of residues in transmembrane II and VII, including Q115, Y119, Y313, I316, and Y320. The mutation of one hydrophobic residue in particular, I316, was found to completely abolish salvinorin A binding. As expected, none of the residues in transmembrane III or VI commonly associated with opiate recognition (such as D138 or E297) appear to be required for ligand binding. On the basis of the results presented here and elsewhere, a binding site model is proposed that aligns salvinorin A vertically within a pocket spanning transmembrane II and VII, with the 2′ substituent directed toward the extracellular domains. The model explains the role that hydrophobic contacts play in binding this lipophilic ligand and gives insight into the structural basis to the μ-opioid receptor selectivity of 2′-benzoyl salvinorin (herkinorin).

AB - The structural basis to salvinorin A recognition of the κ-opioid receptor is evaluated using a combination of site-directed mutagenesis and molecular-modeling techniques. The results show that salvinorin A recognizes a collection of residues in transmembrane II and VII, including Q115, Y119, Y313, I316, and Y320. The mutation of one hydrophobic residue in particular, I316, was found to completely abolish salvinorin A binding. As expected, none of the residues in transmembrane III or VI commonly associated with opiate recognition (such as D138 or E297) appear to be required for ligand binding. On the basis of the results presented here and elsewhere, a binding site model is proposed that aligns salvinorin A vertically within a pocket spanning transmembrane II and VII, with the 2′ substituent directed toward the extracellular domains. The model explains the role that hydrophobic contacts play in binding this lipophilic ligand and gives insight into the structural basis to the μ-opioid receptor selectivity of 2′-benzoyl salvinorin (herkinorin).

UR - http://www.scopus.com/inward/record.url?scp=41149143712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149143712&partnerID=8YFLogxK

U2 - 10.1021/jm701040v

DO - 10.1021/jm701040v

M3 - Article

C2 - 18293909

AN - SCOPUS:41149143712

VL - 51

SP - 1824

EP - 1830

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 6

ER -